Therapeutic monocloncal antibodies (MoAbs) targeting CD38 (daratumumab, isatuximab) and SLAMF7 (elotuzumab) further improved outcomes of patients with relapsed/refractory MM (RRMM) [2,3,4,5]. This evidence concerns the gene SLAMF7 and Miyoshi myopathy.